The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes

被引:15
作者
Bijsterveld, NR
Moons, AH
Meijers, JCM
Levi, M
Büller, HR
Peters, RJG
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1100 DD Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/S0735-1097(03)00653-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to quantify the impact of adding an intravenous loading dose to a subcutaneous regimen of enoxaparin in patients with an acute coronary syndrome (ACS). BACKGROUND It is unclear whether an intravenous (M loading dose of enoxaparin should be added to a subcutaneous (SQ) regimen in patients with ACS. METHODS Patients admitted with ACS were randomized to IV + SQ(n = 14) or SQ alone (n = 11) enoxaparin treatment. Coagulation markers were measured at nine time points during the first 24 h of treatment. RESULTS The TV + SQ therapy immediately resulted in therapeutic anti-Xa levels, which remained significantly higher for 6 h compared with SQ alone, without reaching excessively high levels. A rapid decrease of plasma prothrombin fragments 1 + 2 (F1 + 2) levels was observed as soon as 5 min after the IV injection (33% lower; p = 0.007), and these levels remained lower up to 2 h after the start of treatment compared with SQ alone. The ex vivo thrombin generation time was maximally prolonged at 5 min post-injection in the IV + SQ group and remained significantly prolonged up to 6 h post-injection compared with SQ alone. The tissue factor pathway inhibitor plasma activity was immediately increased by 194% with IV + SQ, whereas the maximum increase with SQ alone was 47% at 3 h. CONCLUSIONS Therapeutic plasma levels of enoxaparin are achieved significantly earlier by an IV + SQ regimen compared with SQ alone, without leading to unacceptably high levels. As the risk of thrombotic complications is greatest early after admission, the observed differences in antithrombotic effects may translate into a clinical benefit. However, this remains to be established. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:424 / 427
页数:4
相关论文
共 11 条
[1]   Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].
Antman, EM ;
McCabe, CH ;
Gurfinkel, EP ;
Turpie, AGG ;
Bernink, PJLM ;
Salein, D ;
de Luna, AB ;
Fox, K ;
Lablanche, JM ;
Radley, D ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1593-1601
[2]  
Braunwald E, 1997, J AM COLL CARDIOL, V29, P1474
[3]   Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity [J].
Caplice, NM ;
Mueske, CS ;
Kleppe, LS ;
Simari, RD .
CIRCULATION, 1998, 98 (11) :1051-1057
[4]   A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [J].
Cohen, M ;
Demers, C ;
Gurfinkel, EP ;
Turpie, AGG ;
Fromell, GJ ;
Goodman, S ;
Langer, A ;
Califf, RM ;
Fox, KAA ;
Premmereur, J ;
Bigonzi, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :447-452
[5]  
Guerrero RAA, 1999, EUR HEART J, V20, P1553
[6]  
Klein W, 1997, CIRCULATION, V96, P61
[7]   Identification of active tissue factor in human coronary atheroma [J].
Marmur, JD ;
Thiruvikraman, SV ;
Fyfe, BS ;
Guhu, A ;
Sharma, SK ;
Ambrose, JA ;
Fallon, JT ;
Nemerson, Y ;
Taubman, MB .
CIRCULATION, 1996, 94 (06) :1226-1232
[8]   Tissue factor modulates the thrombogenicity of human atherosclerotic plaques [J].
Toschi, V ;
Gallo, R ;
Lettino, M ;
Fallon, JT ;
Gertz, SD ;
FernandezOrtiz, A ;
Chesebro, JH ;
Badimon, L ;
Nemerson, Y ;
Fuster, V ;
Badimon, JJ .
CIRCULATION, 1997, 95 (03) :594-599
[9]  
Wallentin L, 1996, LANCET, V347, P561
[10]  
Yusuf S, 2001, NEW ENGL J MED, V345, P494